Specialized Expertise Charles River Discovery (ChanTest) is a highly specialized CRO focused on ion channel and GPCR safety testing for pharmaceutical and biotech clients, making it an ideal partner for companies seeking expert nonclinical screening services to accelerate drug development timelines.

Trusted Industry Leader With a reputation as the most trusted and widely used fee-for-service provider for ion channel screening since 2006, ChanTest offers proven reliability and quality, which can be a strong selling point to prospective clients looking for reputable testing partners.

Growth Potential Operating with a revenue range of 1 million to 10 million and a relatively small team, ChanTest presents an opportunity for strategic collaborations that can help expand its service offerings or market reach within the biotechnology and pharmaceutical sectors.

Global Market Outreach Having served over 300 international pharma and biotech companies since 1998, the company has a solid foundation and potential for scaling its services further across the global drug discovery and development market.

Innovative Service Offerings ChanTest's extensive library of validated ion channel cell lines and comprehensive cardiac risk assessment services position it as a leader in preclinical safety testing, presenting opportunities to upsell or introduce new testing modules to existing and prospective customers.